These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32634775)

  • 21. Real-world data of immunotherapy from China in recurrent or metastatic head and neck squamous cell carcinoma.
    Zhang X; Wang P; Chai Y; Zhou X; Li P; Wang X
    Am J Otolaryngol; 2024; 45(1):104065. PubMed ID: 37879241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review.
    Guidi A; Codecà C; Ferrari D
    Med Oncol; 2018 Feb; 35(3):37. PubMed ID: 29441454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant immunotherapy in head and neck cancer: Rationale, current evidence and future perspective.
    Cabezas-Camarero S; Pérez-Segura P
    Crit Rev Oncol Hematol; 2022 Jan; 169():103569. PubMed ID: 34890800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The 5-Ws of immunotherapy in head and neck cancer.
    Botticelli A; Mezi S; Pomati G; Cerbelli B; Di Rocco C; Amirhassankhani S; Sirgiovanni G; Occhipinti M; Napoli V; Emiliani A; Mazzuca F; Tomao S; Nuti M; Marchetti P
    Crit Rev Oncol Hematol; 2020 Sep; 153():103041. PubMed ID: 32629362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer.
    Yu Y; Lee NY
    Future Oncol; 2019 Mar; 15(7):687-694. PubMed ID: 30461306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck.
    Kacew AJ; Harris EJ; Lorch JH; Schoenfeld JD; Margalit DN; Kass JI; Tishler RB; Haddad RI; Hanna GJ
    Oral Oncol; 2020 Jun; 105():104676. PubMed ID: 32251982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
    Hanna GJ; Adkins DR; Zolkind P; Uppaluri R
    Oral Oncol; 2017 Oct; 73():65-69. PubMed ID: 28939078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapeutic Strategies for Head and Neck Cancer.
    Buchwald ZS; Schmitt NC
    Otolaryngol Clin North Am; 2021 Aug; 54(4):729-742. PubMed ID: 34116846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Efficacy of Cetuximab-Based Salvage Chemotherapy After Checkpoint Inhibitors in Head and Neck Cancer.
    Cabezas-Camarero S; Cabrera-Martín MN; Merino-Menéndez S; Paz-Cabezas M; García-Barberán V; Sáiz-Pardo Sanz M; Iglesias-Moreno M; Alonso-Ovies A; Pérez-Segura P
    Oncologist; 2021 Jun; 26(6):e1018-e1035. PubMed ID: 33751752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Rischin D; Spigel DR; Adkins D; Wein R; Arnold S; Singhal N; Lee O; Murugappan S
    Head Neck; 2016 Apr; 38 Suppl 1():E1756-61. PubMed ID: 26681429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
    Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
    Front Immunol; 2021; 12():645170. PubMed ID: 33897693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
    Ferris RL; Licitra L; Fayette J; Even C; Blumenschein G; Harrington KJ; Guigay J; Vokes EE; Saba NF; Haddad R; Ramkumar S; Russell J; Brossart P; Tahara M; Colevas AD; Concha-Benavente F; Lynch M; Li L; Gillison ML
    Clin Cancer Res; 2019 Sep; 25(17):5221-5230. PubMed ID: 31239321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
    Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
    Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy for head and neck cancer: from recurrent/metastatic disease to (neo)adjuvant treatment in surgically resectable tumors.
    Specenier P
    Curr Opin Otolaryngol Head Neck Surg; 2021 Apr; 29(2):168-177. PubMed ID: 33605624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of HPV status in recurrent/metastatic squamous cell carcinoma of the head and neck.
    Misiukiewicz K; Camille N; Gupta V; Bakst R; Teng M; Miles B; Genden E; Sikora A; Posner M
    Clin Adv Hematol Oncol; 2014 Dec; 12(12):812-9. PubMed ID: 25674839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of chemotherapy after progression with nivolumab in squamous cell carcinoma of the head and neck.
    Suzuki S; Toyoma S; Tomizawa H; Yamada T; Iikawa N; Shiina K; Saito H; Koizumi K; Kawasaki Y; Yamada T
    Auris Nasus Larynx; 2020 Jun; 47(3):485-488. PubMed ID: 31248647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy for Head and Neck Cancer.
    Trivedi S; Sun L; Aggarwal C
    Hematol Oncol Clin North Am; 2021 Oct; 35(5):1021-1037. PubMed ID: 34244017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy.
    Saba NF; Mody MD; Tan ES; Gill HS; Rinaldo A; Takes RP; Strojan P; Hartl DM; Vermorken JB; Haigentz M; Ferlito A
    Crit Rev Oncol Hematol; 2017 Jul; 115():50-58. PubMed ID: 28602169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.